Document Classification

Section Type: RESULTS

Text: The Fenofibrate and omega-3 Fatty Acid Modulation of Endotoxemia (FFAME) study was an 8-wk randomized double-blind trial of placebo or n-3 PUFA supplementation (Lovaza 465 mg eicosapentaenoic acid (EPA) + 375 mg docosahexaenoic acid (DHA)) at '' low '' (1/day, 900 mg) or '' high '' (4/day, 3600 mg) dose in healthy individuals (N = 60 ; age 18-45 ; BMI 18-30 ; 43 % female ; 65 % European -, 20 % African -, 15 % Asian-ancestry) before a low-dose endotoxin challenge (LPS 0. 6 ng/kg intravenous bolus).